Walter E. Cook

Experimental infection of deer with bovine viral diarrhea virus.

In order to determine the susceptibility of deer to infection with bovine viral diarrhea virus (BVDV), four mule deer (Odocoileus hemionus) fawns and one white-tailed deer (O. virginianus) fawn were inoculated intranasally with the New York-1 strain of BVDV originally isolated from cattle. None of the animals developed clinical signs of illness. Virus was isolated from white blood cells from four fawns on one or more occasions from day 2 through day 15 post-inoculation (PI) indicating that infection and systemic spread of BVDV had occurred. In addition, virus was isolated from nasal swabs from three fawns, one to three times, from day 2 through day 8 PI. Four fawns had virus neutralizing antibody titers to two strains of BVDV prior to inoculation and all developed greater than four-fold increases in virus neutralizing antibody titers by 3 wk PI. No gross lesions of bovine viral diarrhea were detected at necropsy approximately 3 mo PI. A variety of nonspecific lesions were detected by histopathology. Based on these findings, mule and white-tailed deer are susceptible to infection with BVDV. Isolation of virus from nasal swabs is evidence that BVDV could be transmitted by deer via direct contact.

Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion.

Brucella abortusstrain RB51 is used as a vaccine because it induces antibodies that do not react on standard serologic tests for brucellosis allowing differentiation between vaccination and infection. Strain RB51 was evaluated in captive elk (Cervus elaphus) to determine if vaccination protected against abortion following experimental challenge. Thirty elk were vaccinated intramuscularly with 1.0 × 1010 colony-forming units (CFU) of strain RB51 in March 1998. Fourteen of these were given a booster dose of 1.13 × 1010 CFU exactly 1 yr later. All vaccinated elk seroconverted via a modified dot blot assay to strain RB51 with the booster group having higher titers (P ≤0.001). Seventeen other elk served as unvaccinated controls. All elk were bred and determined pregnant using pregnancy-specific protein B analysis. Elk were challenged in March 2000 with 1.1 × 107 CFU of B. abortusstrain 2308 administered intraconjunctivally and all elk seroconverted to strain 2308. Fifteen of 17 control elk aborted; 16 of 16 elk given a single vaccination aborted (P = 0.44); and 13 of 14 elk given a booster aborted (P = 0.86). There were two viable calves in the control group and one in the booster group. Strain 2308 was recovered from fetuses and nonviable calves in all groups. Based on the results of this and other studies, the use of strain RB51 to prevent abortion in elk cannot be recommended.

Brucella abortus strain RB51 vaccination in elk. I. Efficacy of reduced dosage.

Bovine brucellosis is a serious zoonotic disease affecting some populations of Rocky Mountain elk (Cervus elaphus nelsoni) and bison (Bison bison) in the Greater Yellowstone Area, USA. The fear that elk and/or bison may spread Brucella abortusto livestock has prompted efforts to reduce or eliminate the disease in wildlife. Brucella abortusstrain RB51 (RB51) vaccine has recently been approved for use in cattle. Unlike strain 19 vaccine, RB51 does not cause false positive reactions on standard brucellosis serologic tests. If effective, it may become the vaccine of choice for wildlife. In February 1995, 45 serologically negative female elk calves were trapped and taken to the Sybille Wildlife Research and Conservation Education Unit near Wheatland, Wyoming, USA. In May 1995, 16 of these elk calves were hand-vaccinated with 1 × 109 colony forming units (CFU) of RB51, 16 were vaccinated with 1 × 108 CFU RB51 by biobullet, and 13 were given a saline placebo. The elk were bred in fall of 1996 and they were challenged with 1 × 107 CFU of B. abortusstrain 2308 by intraconjunctival inoculation in March 1997. Thirteen (100%) control elk aborted, 14 (88%) hand-vaccinated elk aborted, and 12 (75%) biobullet vaccinated elk aborted or produced nonviable calves. These results suggest that a single dose of 1 × 108 to 1 × 109 CFU RB51 does not provide significant protection against B. abortusinduced abortion in elk. However, the vaccine appears to be safe at this dose and additional study may reveal a more effective RB51 vaccine regimen for elk.

Chronic Wasting Disease Drives Population Decline of White-Tailed Deer

Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose. Despite a 100% fatality rate, areas of high prevalence, and increasingly expanding geographic endemic areas, little is known about the population-level effects of CWD in deer. To investigate these effects, we tested the null hypothesis that high prevalence CWD did not negatively impact white-tailed deer population sustainability. The specific objectives of the study were to monitor CWD-positive and CWD-negative white-tailed deer in a high-prevalence CWD area longitudinally via radio-telemetry and global positioning system (GPS) collars. For the two populations, we determined the following: a) demographic and disease indices, b) annual survival, and c) finite rate of population growth (λ). The CWD prevalence was higher in females (42%) than males (28.8%) and hunter harvest and clinical CWD were the most frequent causes of mortality, with CWD-positive deer over-represented in harvest and total mortalities. Survival was significantly lower for CWD-positive deer and separately by sex; CWD-positive deer were 4.5 times more likely to die annually than CWD-negative deer while bucks were 1.7 times more likely to die than does. Population λ was 0.896 (0.859–0.980), which indicated a 10.4% annual decline. We show that a chronic disease that becomes endemic in wildlife populations has the potential to be population-limiting and the strong population-level effects of CWD suggest affected populations are not sustainable at high disease prevalence under current harvest levels.

Paresis and Death in Elk (Cervus elaphus) Due to Lichen Intoxication in Wyoming

During February– April 2004, an estimated 400–500 free-ranging elk (Cervus elaphus) developed paresis, became recumbent, and died or were euthanized in the Red Rim Wildlife Habitat Management Area (RRWHMA), Wyoming, USA. Elk were found in sternal recumbency, alert and responsive, but unable to rise. Their condition progressed to lateral recumbency followed by dehydration, obtundation, and death. Gross lesions were limited to degenerative myopathy, with pallor and streaking in skeletal muscles. Microscopically, affected muscles had degenerative lesions of varying duration, severity, and distribution, some with early mineralization and attempts at regeneration. Diagnostic testing ruled out common infectious, inflammatory, toxic, and traumatic causes. Tumbleweed shield lichen (Xanthoparmelia chlorochroa) was found in the area and in the rumen of several elk. This lichen was collected and fed to three captive elk. Two of these elk exhibited signs of ataxia, which rapidly progressed to weakness and recumbency after 7 and 10 days on this diet, respectively, and a degenerative myopathy, consistent with lesions observed in the elk affected at RRWHMA, was observed. All remaining elk migrated from the RRWHMA during the spring and no subsequent losses have been documented.

Disappearance of bovine fetuses in northwestern Wyoming

Abstract Brucellosis is a bacterial disease of cattle that has become established in elk (Cervus elaphus nelsoni) and bison (Bos bison) of the Greater Yellowstone Area. It causes pregnant elk and bison to abort, and the aborted fetus has the potential to transmit the pathogen to disease-free domestic cattle. We examined how long healthy bovine fetuses, as surrogates for aborted bison or elk fetuses, remained in the environment and could be available for contact by elk, bison, and cattle. Disease-free bovine fetuses were placed on Wyomings National Elk Refuge, state of Wyoming elk feedgrounds, and Grand Teton National Park to simulate aborted elk or bison fetuses. We monitored the fetuses until they disappeared due to scavenging. Fetuses disappeared on average in 26.8 hours (SD=25.3 hours) from the National Elk Refuge, 40.7 hours (SD=31.1 hours) at state elk feed-grounds, and 57.5 hours (SD=48.0 hours) at Grand Teton National Park. Ninety percent of fetuses can be expected to disappear from the National Elk Refuge within 69.5 hours (2.9 days), from state elk feedgrounds within 68.5 hours (2.9 days), and from Grand Teton National Park within 142 hours (5.9 days). The dominant scavengers at all locations were coyotes (Canis latrans), but ravens (Corvus corax), magpies (Pica pica), bald eagles (Haliaeetus leucocephalus), golden eagles (Aquila chrysaetos), turkey vultures (Cathartes aura), red-tailed hawks (Buteo jamaicensis), black bears (Ursus americanus), grizzly bears (U. arctos), and probably elk and bison also participated in scavenging.

VALIDATION OF A BRUCELLA ABORTUS COMPETITIVE ENZYME-LINKED IMMUNOSORBENT ASSAY FOR USE IN ROCKY MOUNTAIN ELK (CERVUS ELAPHUS NELSONI)

Brucellosis caused by infection with Brucella abortus is present in some elk (Cervus elaphus nelsoni) of the Greater Yellowstone Area (parts of Wyoming, Montana, and Idaho, USA). Since 1985, the Wyoming Game and Fish Department has vaccinated elk on elk feedgrounds in northwestern Wyoming during the winter months using B. abortus strain 19 (strain 19). Analysis of this vaccination program is hampered by the inability of standard serologic tests to differentiate between strain 19 vaccinated elk and those exposed to field strain B. abortus. In 1993, a competitive enzyme-linked immunosorbent assay (cELISA) was licensed to serologically differentiate between strain 19 vaccinated cattle and cattle exposed to field strain B. abortus. Seven groups of elk sera representing various B. abortus exposure histories were used to validate the cELISA test for elk. The cELISA test differentiated strain 19 vaccinated elk from elk that were challenged with B. abortus strain 2308, a pathogenic laboratory strain. The specificity of the cELISA was 96.8% for elk vaccinated with strain 19 only and sampled between 6 mo and 2 yr post vaccination, or with no B. abortus exposure. The sensitivity of the cELISA was 100%. The cELISA test will be useful in evaluating sera collected from elk in vaccinated, brucellosis endemic herds in the Greater Yellowstone Area.

Brucellosis in Captive Rocky Mountain Bighorn Sheep (Ovis canadensis) Caused by Brucella abortus Biovar 4

Nine (four female, five male) captive adult Rocky Mountain bighorn sheep (Ovis canadensis) contracted brucellosis caused by Brucella abortus biovar 4 as a result of natural exposure to an aborted elk (Cervus elaphus) fetus. Clinical signs of infection were orchitis and epididymitis in males and lymphadenitis and placentitis with abortion in females. Gross pathologic findings included enlargement of the testes or epididymides, or both, and yellow caseous abscesses and pyogranulomas of the same. Brucella abortus biovar 4 was cultured in all bighorn sheep from a variety of tissues, including testes/epididymides, mammary gland, and lymph nodes. All bighorn sheep tested were positive on a variety of standard Brucella serologic tests. This is the first report of brucellosis caused by B. abortus in Rocky Mountain bighorn sheep. It also provides evidence that bighorn sheep develop many of the manifestations ascribed to this disease and that infection can occur from natural exposure to an aborted fetus from another species. Wildlife managers responsible for bighorn sheep populations sympatric with Brucella-infected elk or bison (Bison bison) should be cognizant of the possibility of this disease in bighorn sheep.

SAFETY OF BRUCELLA ABORTUS STRAIN RB51 VACCINE IN NON-TARGET UNGULATES AND COYOTES

Brucellosis is endemic in free-ranging elk (Cervus elaphus) and bison (Bison bison) in the Greater Yellowstone Area (GYA; USA). It is possible that an oral brucellosis vaccine could be developed and disseminated in the GYA to reduce disease transmission. Should this occur, non-target species other than elk and bison may come in contact with the vaccine resulting in morbidity or mortality. To assess biosafety, bighorn sheep (Ovis canadensis; n=10), pronghorn (Antilocapra americana; n=9), mule deer (Odocoileus hemionus; n=11), moose (Alces alces shirasi; n=10), and coyotes (Canis latrans; n=24) were given a single oral dose of at least 1.0×1010 colony-forming units of Brucella abortus strain RB51 vaccine (RB51). Animals were randomly divided into vaccinated and control groups. Ungulates were captured, blood sampled, and swabs taken from the nares, rectum, and vagina for bacterial culture on day 0, 42, and 84 post-inoculation (PI). On day 42, the vaccinated group became a control group and vice versa in a crossover design. Blood and swab samples were taken from coyotes on days 0, 14, 28, and 42 PI. There was no crossover for the coyote study. Two coyotes from each group were also euthanized and cultured for RB51 on days 42, 84, 168, and 336 PI. Blood samples were analyzed for hematologic changes and antibodies to RB51 using a modified dot-blot assay. No morbidity or mortality as a result of vaccination was observed in any animal. There were no differences in hematologic parameters at any time for ungulate species; vaccinated coyotes had higher hematocrit, hemoglobin, and eosinophil counts (P≤0.006). All individuals, except some moose, seroconverted to RB51. Strain RB51 was cultured from oropharyngeal lymph nodes from one coyote 42 days PI and from a moose 117 days PI. This study suggested that a single oral dose of RB51 was safe in these species.

Anesthesia of pronghorns using thiafentanil or thiafentanil plus xylazine

Thiafentanil is a potent synthetic opioid anesthetic being developed for wildlife anesthesia. Thiafentanil was tested for safety and efficacy on free-ranging pronghorn (Antilocapra americana) inhabiting F. E. Warren Air Force Base in southeastern Wyoming. Pronghorn were darted with pre-measured dosages of either 4.0 or 5.0 mg of thiafentanil without (group 1) or with (group 2) the addition of 25.0 mg xylazine Seventeen pronghorn were captured in group 1 and 14 pronghorn in group 2. There were no differences between groups for capture times or physiological parameters (P ≥ 0.21). Anesthetic induction was rapid for both groups (≤ 2.7 ± 0.4 min) as was recovery after antagonism (≤ 0.7 ± 0.07 min). The dosage of thiafentanil administered was 0.10 ± 0.005 mg/kg and the dosage of xylazine was 0.56 ± 0.03 mg/kg. Anesthesia in both groups was characterized by muscle rigidity and rapid, shallow respiration. Twenty-five pronghorn were radiocollared and survived ≥21 days after capture. One adult male in group 1 died during capture. Thiafentanil was considered more effective on pronghorn than carfentanil-xylazine, ketamine-xylazine, or tiletamine-zolazepam-xylazine anesthetic regimens.